Recommended Topic Related To:

Kadian

"The U.S. Food and Drug Administration has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications “ Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North Ameri"...

Kadian

Kadian

INDICATIONS

KADIAN is indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Limitations of Use

Kadian is not for use:

  • As an as-needed (prn) analgesic
  • For pain that is mild or not expected to persist for an extended period of time
  • For acute pain
  • For postoperative pain unless the patient is already receiving chronic opioid therapy prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time.

Kadian 100 mg, 130 mg, 150 mg, and 200 mg capsules are only for patients in whom tolerance to an opioid of comparable potency is established. Patients considered opioid-tolerant are those taking at least 60 mg of morphine daily, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer.

DOSAGE AND ADMINISTRATION

Initial Dosing

Initiate the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with KADIAN [see WARNINGS AND PRECAUTIONS].

Consider the following factors when selecting an initial dose of KADIAN:

  • Total daily dose, potency, and any prior opioid the patient has been taking previously;
  • Reliability of the relative potency estimate used to calculate the equivalent dose of morphine needed (Note: potency estimates may vary with the route of administration);
  • Patient's degree of opioid experience and opioid tolerance;
  • General condition and medical status of the patient;
  • Concurrent medication;
  • Type and severity of the patient's pain.

KADIAN is administered at a frequency of either once daily (every 24 hours) or twice daily (every 12 hours).

Use of KADIAN as the First Opioid Analgesic

There has been no evaluation of KADIAN as an initial opioid analgesic in the management of pain. Because it may be more difficult to titrate a patient to adequate analgesia using an extended-release morphine, begin treatment using an immediate-release morphine formulation and then convert patients to KADIAN as described below.

Conversion from Other Oral Morphine Formulations to KADIAN

Patients receiving other oral morphine formulations may be converted to KADIAN by administering one-half of the patient's total daily oral morphine dose as KADIAN twice daily or by administering the total daily oral morphine dose as KADIAN once daily. There are no data to support the efficacy or safety of prescribing KADIAN more frequently than every 12 hours.

KADIAN is not bioequivalent to other extended-release morphine preparations. Conversion from KADIAN to the same total daily dose of another extended-release morphine product may lead to either excessive sedation at peak or inadequate analgesia at trough. Therefore, monitor patients closely when initiating KADIAN therapy and adjust the dosage of KADIAN as needed.

Conversion from Parenteral Morphine, or Other Opioids to KADIAN

While there are useful tables of oral and parenteral equivalents, there is substantial inter-patient variation in the relative potency of different opioid drugs and formulations. As such, it is safer to underestimate a patient's 24-hour oral morphine requirement and provide rescue medication (e.g. immediate-release morphine) than to overestimate and manage an adverse reaction. Consider the following general points:

Parenteral to Oral Morphine Ratio: Between 2 mg and 6 mg of oral morphine may be required to provide analgesia equivalent to 1 mg of parenteral morphine. Typically, a dose of oral morphine that is three times the daily parenteral morphine requirement is sufficient.

Other Oral or Parenteral Opioids to Oral Morphine Sulfate: Specific recommendations are not available because of a lack of systematic evidence for these types of analgesic substitutions. Published relative potency data are available, but such ratios are approximations. In general, begin with half of the estimated daily morphine requirement as the initial dose, managing inadequate analgesia by supplementation with immediate-release morphine.

The first dose of KADIAN may be taken with the last dose of any immediate-release opioid medication due to the extended-release characteristics of the KADIAN formulation.

Titration and Maintenance of Therapy

Individually titrate KADIAN to a dose that provides adequate analgesia and minimizes adverse reactions at a frequency of either once or twice daily. Continually reevaluate patients receiving KADIAN to assess the maintenance of pain control and the relative incidence of adverse reactions. During chronic therapy, especially for non-cancer-related pain (or pain associated with other terminal illnesses), periodically reassess the continued need for the use of opioid analgesics.

If the level of pain increases, attempt to identify the source of increased pain, while adjusting the KADIAN dose to decrease the level of pain. Because steady-state plasma concentrations are approximated within 24 to 36 hours, KADIAN dosage adjustments may be done every 1 to 2 days. Patients who experience breakthrough pain may require dosage adjustment or rescue medication with a small dose of an immediate-release medication. In patients experiencing inadequate analgesia with once daily dosing of KADIAN, consider a twice daily regimen.

If signs of excessive opioid-related adverse reactions are observed, the next dose may be reduced. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

Discontinuation of KADIAN

When a patient no longer requires therapy with KADIAN, use a gradual downward titration, of the dose every two to four days, to prevent signs and symptoms of withdrawal in the physically-dependent patient. Do not abruptly discontinue KADIAN.

Administration of KADIAN

Instruct patients to swallow KADIAN capsules intact. The pellets in the capsules are not to be crushed, dissolved, or chewed due to the risk of rapid release and absorption of a potentially fatal dose of morphine [see WARNINGS AND PRECAUTIONS].

Alternatively, the contents of the KADIAN capsules (pellets) may be sprinkled over applesauce and then swallowed. This method is appropriate only for patients able to reliably swallow the applesauce without chewing. Other foods have not been tested and should not be substituted for applesauce. Instruct the patient to:

  • Sprinkle the pellets onto a small amount of applesauce and consume immediately without chewing.
  • Rinse the mouth to ensure all pellets have been swallowed.
  • Discard any unused portion of the KADIAN capsules after the contents have been sprinkled on applesauce.

The contents of the Kadian capsules (pellets) may be administered through a 16 French gastrostomy tube.

  1. Flush the gastrostomy tube with water to ensure that it is wet.
  2. Sprinkle the KADIAN Pellets into 10 mL of water.
  3. Use a swirling motion to pour the pellets and water into the gastrostomy tube through a funnel.
  4. Rinse the beaker with a further 10 mL of water and pour this into the funnel.
  5. Repeat rinsing until no pellets remain in the beaker.

Do not administer KADIAN pellets through a nasogastric tube.

HOW SUPPLIED

Dosage Forms And Strengths

KADIAN contains white to off-white or tan colored polymer coated pellets, have an outer opaque capsule with colors as identified below and are available in twelve dose strengths:

Each 10 mg capsule has a light blue opaque cap printed with “KADIAN” and a light blue opaque body printed with “10 mg”.

Each 20 mg capsule has a yellow opaque cap printed with “KADIAN” and a yellow opaque body printed with “20 mg”.

Each 30 mg capsule has a blue violet opaque cap printed with “KADIAN” and a blue violet opaque body printed with “30 mg”.

Each 40 mg capsule has a yellow opaque cap printed with “KADIAN” and a blue violet opaque body printed with “40 mg”.

Each 50 mg capsule has a blue opaque cap printed with “KADIAN” and a blue opaque body printed with “50 mg”.

Each 60 mg capsule has a pink opaque cap printed with “KADIAN” and a pink opaque body printed with “60 mg”.

Each 70 mg capsule has a light blue opaque cap printed with “KADIAN” and a blue violet opaque body printed with “70 mg”.

Each 80 mg capsule has a light orange opaque cap printed with “KADIAN” and a light orange opaque body printed with “80 mg”.

Each 100 mg capsule has a green opaque cap printed with “KADIAN” and a green opaque body printed with “100 mg”.

Each 130 mg capsule has a light orange opaque cap printed with “KADIAN” and a light brown opaque body printed with “130 mg”.

Each 150 mg capsule has a green opaque cap printed with “KADIAN” and a light brown opaque body printed with “150 mg”.

Each 200 mg capsule has a light brown opaque cap printed with “KADIAN” and light brown opaque body printed with “200 mg”.

Storage And Handling

KADIAN capsules contain white to off-white or tan colored polymer coated extended-release pellets of morphine sulfate and are available in twelve dose strengths.

  KADIAN 10 mg KADIAN 20 mg KADIAN 30 mg KADIAN 40 mg
Capsule Description size 4, light blue opaque cap printed with “KADIAN” and light blue opaque body printed with “10 mg”. size 4, yellow opaque cap printed with “KADIAN” and yellow opaque body printed with “20 mg”. size 4, blue violet opaque cap printed with “KADIAN” and blue violet opaque body printed with “30 mg”. size 2, yellow opaque cap printed with “KADIAN” and blue violet opaque body printed with “40 mg”.
Bottle Size 100 100 100 100
NDC # NDC 46987-410-11 NDC 46987-322-11 NDC 46987-325-11 NDC 46987-327-11
  KADIAN 50 mg KADIAN 60 mg KADIAN 70 mg KADIAN 80 mg
Capsule Description size 2, blue opaque cap printed with “KADIAN” and blue opaque body printed with “50 mg”. size 1, pink opaque cap printed with “KADIAN” and pink opaque body printed with “60 mg”. size 1EL, light blue opaque cap printed with “KADIAN” and blue violet opaque body printed with “70 mg”. size 0, light orange opaque cap printed with “KADIAN” and light orange opaque body printed with “80 mg”.
Bottle Size 100 100 100 100
NDC # NDC 46987-323-11 NDC 46987-326-11 NDC 46987-328-11 NDC 46987-412-11
  KADIAN 100 mg KADIAN 130 mg KADIAN 150 mg KADIAN 200 mg
Capsule Description size 0, green opaque cap printed with “KADIAN” and green opaque body printed with “100 mg”. size 1, light orange opaque cap printed with “KADIAN” and light brown opaque body printed with “130 mg”. size 1EL, green opaque cap printed with “KADIAN” and light brown opaque body printed with “150 mg”. size 0, light brown opaque cap printed with “KADIAN” and light brown opaque body printed with “200 mg”.
Bottle Size 100 100 100 100
NDC # NDC 46987-324-11 NDC 46987-329-11 NDC 46987-330-11 NDC 46987-377-11

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). Protect from light and moisture. Dispense in a sealed tamper-evident, childproof, light-resistant container.

Distributed by: Actavis Kadian LLC, 60 Columbia Rd., Bldg. B, Morristown, NJ 07960 USA. Revised: July 2012

Last reviewed on RxList: 7/23/2012
This monograph has been modified to include the generic and brand name in many instances.

A A A

Kadian - User Reviews

Kadian User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Kadian sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Chronic Pain/Back Pain

Find tips and advances in treatment.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations